Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 611 to 620 of 2733 total matches.

Fluvoxamine for COVID-19?

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
for treatment of COVID-19,1 and several monoclonal antibodies have been granted emergency use authorizations ...
A recent article in JAMA and an interview of its senior author on 60 Minutes have heightened interest in off-label use of the oral selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Luvox, and generics) to treat COVID-19.
Med Lett Drugs Ther. 2021 May 3;63(1623):69-70 |  Show IntroductionHide Introduction

In Brief: A New OTC Naloxone Nasal Spray (RiVive)

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024  (Issue 1698)
) product for emergency treatment of opioid overdose.1 Two 4-mg naloxone nasal spray formulations, Narcan ...
The FDA has approved RiVive (Harm Reduction Therapeutics), a 3-mg naloxone nasal spray, as an over-the-counter (OTC) product for emergency treatment of opioid overdose. Two 4-mg naloxone nasal spray formulations, Narcan and one of its generics, were approved for OTC sale in 2023.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):47-8   doi:10.58347/tml.2024.1698d |  Show IntroductionHide Introduction

In Brief: Erzofri — Another Once-Monthly Paliperidone Formulation (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
formulations of paliperidone palmitate are also available (see Table 1).1 Table 1. Paliperidone Palmitate ...
The FDA has approved Erzofri (Luye), an extended-release injectable formulation of the second-generation antipsychotic drug paliperidone palmitate, for treatment of schizophrenia and schizoaffective disorder in adults. It is the second once-monthly formulation of paliperidone palmitate to be approved in the US for these indications; Invega Sustenna was the first. Longer-acting injectable formulations of paliperidone palmitate are also available (see Table 1).
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e171   doi:10.58347/tml.2024.1713j |  Show IntroductionHide Introduction

Metaglip and Avandamet for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2002  (Issue 1146)
DIABETES Drug Tablet strength Usual daily dosage Cost 1 Metformin − average generic price 500 mg 1500 ...
Two new fixed-dose combinations are now available for management of type 2 diabetes. Metaglip (Bristol-Myers Squibb), a combination of metformin and glipizide, is approved for initial therapy or as second-line treatment when control is not adequate on metformin or a sulfonylurea alone. Avandamet (GlaxoSmithKline), a combination of metformin and rosiglitazone, is approved by the FDA only as second-line therapy for patients who are not well controlled on metformin alone, or are already taking both metformin and rosiglitazone. Glucovance (Bristol-Myers Squibb), a combination of metformin and...
Med Lett Drugs Ther. 2002 Dec 23;44(1146):107-9 |  Show IntroductionHide Introduction

Once-Daily Mesalamine (Lialda) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 2007  (Issue 1257)
not reach the colon. 1 Asacol tablets are coated with a pH-sensitive film that protects mesalamine ...
A once-daily oral formulation of mesalamine (Lialda - Shire) was recently approved by the FDA for induction of remission in patients with mild to moderate ulcerative colitis.
Med Lett Drugs Ther. 2007 Mar 26;49(1257):25-6 |  Show IntroductionHide Introduction

Oritavancin (Orbactiv) for Skin and Skin Structure Infections

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
to be marketed in the US; telavancin (Vibativ) and dalbavancin (Dalvance) were approved earlier.1,2 Oritavancin ...
The FDA has approved oritavancin (Orbactiv – The Medicines Company), a long-acting lipoglycopeptide antibiotic given as a single intravenous (IV) dose, for treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria in adults. It is the third lipoglycopeptide antibiotic to be marketed in the US; telavancin (Vibativ) and dalbavancin (Dalvance) were approved earlier.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):3-5 |  Show IntroductionHide Introduction

Prucalopride (Motegrity) for Chronic Idiopathic Constipation

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
of anal blockage or incomplete evacuation, and a need for manual maneuvers to aid defecation.1 ...
The FDA has approved the 5-HT4 receptor agonist prucalopride (Motegrity – Shire) for treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride is the only drug currently approved in the US for treatment of CIC that stimulates colonic peristalsis. It has been available in Europe and Canada for several years.
Med Lett Drugs Ther. 2019 Jun 3;61(1573):86-8 |  Show IntroductionHide Introduction

Atogepant (Qulipta) for Migraine Prevention

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
in the US for this indication; the first was rimegepant (Nurtec ODT), which is also approved for acute treatment of migraine.1 ...
Atogepant (Qulipta – Abbvie), an oral small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant"), has been approved by the FDA for prevention of episodic migraine in adults. It is the second oral CGRP receptor antagonist to be approved in the US for this indication; the first was rimegepant (Nurtec ODT), which is also approved for acute treatment of migraine. Parenteral CGRP monoclonal antibodies are approved for prevention of migraine (see Table 3).
Med Lett Drugs Ther. 2021 Nov 1;63(1636):169-71 |  Show IntroductionHide Introduction

Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
for treatment of nAMD and DME (see Table 2).1,2 Pronunciation Key Faricimab: far ik’ i mab Vabysmo: vah buys ...
Faricimab-svoa (Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Med Lett Drugs Ther. 2022 Mar 21;64(1646):45-6 |  Show IntroductionHide Introduction

Lumateperone (Caplyta) for Adjunctive Treatment of Depression

   
The Medical Letter on Drugs and Therapeutics • Feb 02, 2026  (Issue 1747)
was approved earlier for treatment of schizophrenia and bipolar depression.1,2 ADJUNCTIVE TREATMENT ...
The FDA has approved the second-generation antipsychotic drug lumateperone (Caplyta — Intra-Cellular Therapies) for adjunctive treatment of major depressive disorder (MDD) in adults. Lumateperone was approved earlier for treatment of schizophrenia and bipolar depression.
Med Lett Drugs Ther. 2026 Feb 2;68(1747):20-2   doi:10.58347/tml.2026.1747c |  Show IntroductionHide Introduction